These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32028557)

  • 1. A Validated IVRT Method to Assess Topical Creams Containing Metronidazole Using a Novel Approach.
    Rath S; Kanfer I
    Pharmaceutics; 2020 Feb; 12(2):. PubMed ID: 32028557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comprehensively validated IVRT method reliably discriminates sameness and differences between several topical clotrimazole creams.
    Wellington H; Rath S; Kanfer I
    Eur J Pharm Sci; 2024 Jan; 192():106649. PubMed ID: 37992910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In Vitro-In Vivo Correlations (IVIVC) for Predicting the Clinical Performance of Metronidazole Topical Creams Intended for Local Action.
    Rath S; Kanfer I
    Pharmaceutics; 2023 Jan; 15(1):. PubMed ID: 36678897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of a dermatopharmacokinetic (DPK) method for bioequivalence assessment of topical metronidazole creams.
    Rath S; Ramanah A; Bon C; Kanfer I
    J Pharm Pharm Sci; 2020; 23():437-450. PubMed ID: 33156995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of an Optimized Tape Stripping Method for the Bioequivalence Assessment of Topical Acyclovir Creams.
    Nallagundla S; Patnala S; Kanfer I
    AAPS PharmSciTech; 2018 May; 19(4):1567-1573. PubMed ID: 29484615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comprehensive approach to qualify and validate the essential parameters of an in vitro release test (IVRT) method for acyclovir cream, 5.
    Tiffner KI; Kanfer I; Augustin T; Raml R; Raney SG; Sinner F
    Int J Pharm; 2018 Jan; 535(1-2):217-227. PubMed ID: 28935255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro release test (IVRT): Principles and applications.
    Shah VP; Simona Miron D; Ștefan Rădulescu F; Cardot JM; Maibach HI
    Int J Pharm; 2022 Oct; 626():122159. PubMed ID: 36067919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative in vitro release testing (IVRT) of acyclovir products.
    Tiffner KI; Kanfer I; Augustin T; Raml R; Raney SG; Sinner F
    Int J Pharm; 2021 Nov; 609():121186. PubMed ID: 34655706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drilling down the bioequivalence assessment of topical antifungal products: Microstructure and release.
    Miranda M; Cardoso C; Pais AACC; Brown M; Vitorino C
    Eur J Pharm Biopharm; 2023 Apr; 185():94-106. PubMed ID: 36806630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diving into Batch-to-Batch Variability of Topical Products-a Regulatory Bottleneck.
    Miranda M; Cova T; Augusto C; Pais AACC; Cardoso C; Vitorino C
    Pharm Res; 2020 Oct; 37(11):218. PubMed ID: 33037479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the hanson microette and the Van Kel apparatus for in vitro release testing of topical semisolid formulations.
    Rapedius M; Blanchard J
    Pharm Res; 2001 Oct; 18(10):1440-7. PubMed ID: 11697470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of local bioavailability of metronidazole from topical formulations using dermal microdialysis: Preliminary study in a Yucatan mini-pig model.
    Kuzma BA; Senemar S; Ramezanli T; Ghosh P; Raney SG; Stagni G
    Eur J Pharm Sci; 2021 Apr; 159():105741. PubMed ID: 33540039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. aQbD as a platform for IVRT method development - A regulatory oriented approach.
    Miranda M; Pais AACC; Cardoso C; Vitorino C
    Int J Pharm; 2019 Dec; 572():118695. PubMed ID: 31536762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reliability and reproducibility of vertical diffusion cells for determining release rates from semisolid dosage forms.
    Hauck WW; Shah VP; Shaw SW; Ueda CT
    Pharm Res; 2007 Nov; 24(11):2018-24. PubMed ID: 17530388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The dose-duration effect on cutaneous pharmacokinetics of metronidazole from topical dermatological formulations in Yucatan mini-pigs.
    Kuzma BA; Senemar S; Ramezanli T; Ghosh P; Raney SG; Stagni G
    Eur J Pharm Biopharm; 2022 Jun; 175():43-52. PubMed ID: 35526809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of optimal in vitro release and permeation testing method for rectal suppositories.
    Srivatsa Palakurthi S; Bharat Charbe N; Recalde Phillips SY; Alge DL; Lu D; Palakurthi S
    Int J Pharm; 2023 Jun; 640():123042. PubMed ID: 37178789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Analytical Target Profile for the Development of an In Vitro Release Test Method and Apparatus Selection in the Case of Semisolid Topical Formulations.
    Szoleczky R; Kovács A; Berkó S; Budai-Szűcs M
    Pharmaceutics; 2024 Feb; 16(3):. PubMed ID: 38543207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are European marketed acyclovir 5% cream products similar? Comparison with EU and US reference product.
    Miron DS; Rădulescu FȘ; Voicu VA; Mînea A; Cardot JM; Shah VP
    Drug Dev Ind Pharm; 2021 Jun; 47(6):990-1000. PubMed ID: 34279163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of oral metronidazole with vaginal clindamycin or vaginal probiotic for bacterial vaginosis: randomised placebo-controlled double-blind trial.
    Bradshaw CS; Pirotta M; De Guingand D; Hocking JS; Morton AN; Garland SM; Fehler G; Morrow A; Walker S; Vodstrcil LA; Fairley CK
    PLoS One; 2012; 7(4):e34540. PubMed ID: 22509319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory Requirements for the Development of Second-Entry Semisolid Topical Products in the European Union.
    García-Arieta A; Gordon J; Gwaza L; Merino V; Mangas-Sanjuan V
    Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.